{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:11:03Z","timestamp":1782029463581,"version":"3.54.5"},"reference-count":63,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board and Breakthrough Cancer Research","doi-asserted-by":"publisher","award":["MRCG-2018-24"],"award-info":[{"award-number":["MRCG-2018-24"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Oesophageal adenocarcinoma (OAC) incidence has increased dramatically in the developed world, yet outcomes remain poor. Extensive endoscopic surveillance programs among patients with Barrett\u2019s oesophagus (BO), the precursor lesion to OAC, have aimed to both prevent the development of OAC via radiofrequency ablation (RFA) and allow earlier detection of disease. However, given the low annual progression rate and the costs of endoscopy\/RFA, improvement is needed. Prognostic biomarkers to stratify BO patients based on their likelihood to progress would enable a more targeted approach to surveillance and RFA of high-risk precursor lesions, improving the cost\u2013risk\u2013benefit ratio. Similarly, diagnostic biomarkers for OAC could enable earlier diagnosis of disease by allowing broader population screening. Current standard treatment for locally advanced OAC includes neoadjuvant chemotherapy (+\/\u2212 radiotherapy) despite only a minority of patients benefiting from neoadjuvant treatment. Accordingly, biomarkers predictive of response to neoadjuvant therapy could improve patient outcomes by reducing time to surgery and unnecessary toxicity for the patients who would have received no benefit from the therapy. In this mini-review, we will discuss the emerging biomarkers which promise to dramatically improve patient outcomes along the BO-OAC disease sequence.<\/jats:p>","DOI":"10.3390\/cancers14143427","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:17:10Z","timestamp":1657844230000},"page":"3427","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic, Diagnostic and Predictive Biomarkers in the Barrett\u2019s Oesophagus-Adenocarcinoma Disease Sequence"],"prefix":"10.3390","volume":"14","author":[{"given":"Darragh","family":"O\u2019Dowd","sequence":"first","affiliation":[{"name":"Department of Surgery, Trinity Translational Medicine Institute, Trinity St. James\u2019s Cancer Institute, Trinity College Dublin, St. James\u2019s Hospital, D08 W9RT Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacintha","family":"O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"Department of Surgery, Trinity Translational Medicine Institute, Trinity St. James\u2019s Cancer Institute, Trinity College Dublin, St. James\u2019s Hospital, D08 W9RT Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5516-4000","authenticated-orcid":false,"given":"Simone","family":"Marcone","sequence":"additional","affiliation":[{"name":"Department of Surgery, Trinity Translational Medicine Institute, Trinity St. James\u2019s Cancer Institute, Trinity College Dublin, St. James\u2019s Hospital, D08 W9RT Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.21037\/acs.2017.03.06","article-title":"Pathology of esophageal cancer and Barrett\u2019s esophagus","volume":"6","author":"Jain","year":"2017","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.gie.2019.05.012","article-title":"ASGE guideline on screening and surveillance of Barrett\u2019s esophagus","volume":"90","author":"Qumseya","year":"2019","journal-title":"Gastrointest. Endosc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/gutjnl-2013-305372","article-title":"British Society of Gastroenterology guidelines on the diagnosis and management of Barrett\u2019s oesophagus","volume":"63","author":"Fitzgerald","year":"2014","journal-title":"Gut"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0042-122140","article-title":"Endoscopic management of Barrett\u2019s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement","volume":"49","author":"Weusten","year":"2017","journal-title":"Endoscopy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00268-014-2661-5","article-title":"Surveillance for Low-Grade Dysplastic Barrett\u2019s Oesophagus: One Size Fits All?","volume":"39","author":"Zaninotto","year":"2015","journal-title":"World J. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.2014.2511","article-title":"Radiofrequency Ablation vs. Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia","volume":"311","author":"Phoa","year":"2014","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1053\/j.gastro.2012.05.010","article-title":"The Cost Effectiveness of Radiofrequency Ablation for Barrett\u2019s Esophagus","volume":"143","author":"Hur","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2016.12.037","article-title":"Risk of oesophageal adenocarcinoma in individuals with Barrett\u2019s oesophagus","volume":"75","author":"Holmberg","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/dote.12166","article-title":"A Barrett\u2019s esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia","volume":"28","author":"PPicardo","year":"2015","journal-title":"Dis. Esophagus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2017.07.046","article-title":"The Epidemiology of Esophageal Adenocarcinoma","volume":"154","author":"Coleman","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_11","first-page":"234","article-title":"International trends in oesophageal cancer survival by histological subtype between 1995 and 2014","volume":"70","author":"Morgan","year":"2021","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.gastro.2015.04.053","article-title":"Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma","volume":"149","author":"Rubenstein","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-med-050715-104218","article-title":"Esophageal Adenocarcinoma: Screening, Surveillance, and Management","volume":"68","author":"Mansour","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1365-2168.2001.01670.x","article-title":"Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer","volume":"88","author":"Geh","year":"2002","journal-title":"Br. J. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/hex.12817","article-title":"Barrett\u2019s oesophagus: A qualitative study of patient burden, care delivery experience and follow-up needs","volume":"22","author":"Britton","year":"2019","journal-title":"Health Expect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.gie.2017.01.007","article-title":"Barrett\u2019s esophagus: Diagnosis and management","volume":"85","author":"Eluri","year":"2017","journal-title":"Gastrointest. Endosc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/j.gastro.2016.09.040","article-title":"Diagnosis and Management of Low-Grade Dysplasia in Barrett\u2019s Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association","volume":"151","author":"Wani","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/his.13462","article-title":"Improved diagnostic stratification of digitised Barrett\u2019s oesophagus biopsies by p53 immunohistochemical staining","volume":"72","author":"Duits","year":"2018","journal-title":"Histopathology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1136\/gutjnl-2012-303594","article-title":"Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett\u2019s oesophagus","volume":"62","author":"Kastelein","year":"2013","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/gcc.22220","article-title":"Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett\u2019s esophagus progression prediction: A prospective follow-up study","volume":"54","author":"Davelaar","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.gastro.2018.03.047","article-title":"Detection of mutations in Barrett\u2019s esophagus before progression to high-grade dysplasia or adenocarcinoma","volume":"155","author":"Stachler","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"doy102","DOI":"10.1093\/dote\/doy102","article-title":"A biomarker panel predicts progression of Barrett\u2019s esophagus to esophageal adenocarcinoma","volume":"32","author":"Duits","year":"2019","journal-title":"Dis. Esophagus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/gutjnl-2015-309642","article-title":"Derivation of genetic biomarkers for cancer risk stratification in Barrett\u2019s oesophagus: A prospective cohort study","volume":"65","author":"Timmer","year":"2016","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000341498","article-title":"Barrett\u2019s to Oesophageal Cancer Sequence: A Model of Inflammatory-Driven Upper Gastrointestinal Cancer","volume":"29","author":"Picardo","year":"2012","journal-title":"Dig. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"O\u2019Farrell, N.J., Phelan, J.J., Feighery, R., Doyle, B., Picardo, S.L., Ravi, N., O\u2019Toole, D., Reynolds, J.V., and O\u2019Sullivan, J. (2019). Differential Expression Profiles of Oxidative Stress Levels, 8-oxo-dG and 4-HNE, in Barrett\u2019s Esophagus Compared to Esophageal Adenocarcinoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184449"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41416-019-0685-1","article-title":"Novel biomarkers for risk stratification of Barrett\u2019s oesophagus associated neoplastic progression\u2013epithelial HMGB1 expression and stromal lymphocytic phenotype","volume":"122","author":"Porter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.dld.2012.12.020","article-title":"Epidemiology and risk factors for oesophageal adenocarcinoma","volume":"45","author":"Lepage","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/gutjnl-2014-308865","article-title":"Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett\u2019s oesophagus","volume":"65","author":"Naik","year":"2016","journal-title":"Gut"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1440-1746.2010.06506.x","article-title":"Is endoscopic surveillance for non-dysplastic Barrett\u2019s esophagus cost-effective? Review of economic evaluations","volume":"26","author":"Hirst","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJMoa1103042","article-title":"Incidence of Adenocarcinoma among Patients with Barrett\u2019s Esophagus","volume":"365","author":"Pedersen","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1158\/1078-0432.CCR-19-0740","article-title":"Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma","volume":"25","author":"Qin","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.1098119","article-title":"Ultraconserved elements in the human genome","volume":"304","author":"Bejerano","year":"2004","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.18632\/oncotarget.2249","article-title":"Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett\u2019s esophagus carcinogenesis","volume":"5","author":"Fassan","year":"2014","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Song, J.H., Tieu, A.H., Cheng, Y., Ma, K., Akshintala, V.S., Simsek, C., Prasath, V., Shin, E.J., Ngamruengphong, S., and Khashab, M.A. (2021). Novel long noncoding RNA miR205HG functions as an esophageal tumor-suppressive hedgehog inhibitor. Cancers, 13.","DOI":"10.3390\/cancers13071707"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-019-1064-5","article-title":"LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma","volume":"18","author":"Xu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.gie.2015.11.031","article-title":"Volatile organic compounds in plasma for the diagnosis of esophageal adenocarcinoma: A pilot study","volume":"84","author":"Bhatt","year":"2016","journal-title":"Gastrointest. Endosc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaoncol.2018.0991","article-title":"Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer","volume":"4","author":"Markar","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jcp.25056","article-title":"MicroRNA as biomarkers and diagnostics","volume":"231","author":"Wang","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1007\/s11605-015-2829-9","article-title":"Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma","volume":"19","author":"Chiam","year":"2015","journal-title":"J. Gastrointest. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"152907","DOI":"10.1016\/j.prp.2020.152907","article-title":"Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett\u2019s carcinogenesis","volume":"216","author":"Fassan","year":"2020","journal-title":"Pathol.-Res. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11605-019-04456-x","article-title":"Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett\u2019s Esophagus to Esophageal Adenocarcinoma: A Cross-Sectional Retrospective Study","volume":"24","author":"Campos","year":"2020","journal-title":"J. Gastrointest. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1038\/s41598-019-41490-w","article-title":"Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma","volume":"9","author":"Haboubi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cgh.2018.07.043","article-title":"Safety and acceptability of esophageal cytosponge cell collection device in a pooled analysis of data from individual patients","volume":"17","author":"Januszewicz","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","article-title":"Oesophageal cancer","volume":"3","author":"Smyth","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-009-0862-1","article-title":"Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer","volume":"17","author":"Meredith","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/gutjnl-2015-310888","article-title":"The prognostic value of TP53 mutations in oesophageal adenocarcinoma: A systematic review and meta-analysis","volume":"66","author":"Fisher","year":"2017","journal-title":"Gut"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.jtcvs.2014.06.079","article-title":"The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study","volume":"148","author":"Kandioler","year":"2014","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/bjs5.50277","article-title":"Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma","volume":"4","author":"Powell","year":"2020","journal-title":"BJS Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s12032-013-0596-6","article-title":"The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer","volume":"30","author":"Noble","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1002\/cncr.28911","article-title":"A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma","volume":"120","author":"Skinner","year":"2014","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bibby, B.A.S., Reynolds, J.V., and Maher, S.G. (2015). MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134180"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1245\/s10434-018-6626-z","article-title":"Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing","volume":"25","author":"Chiam","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/SLA.0b013e31823699f2","article-title":"Serum Proteomic Profiling Reveals That Pretreatment Complement Protein Levels are Predictive of Esophageal Cancer Patient Response to Neoadjuvant Chemoradiation","volume":"254","author":"Maher","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2119\/molmed.2016.00020","article-title":"Low MiR-187 Expression Promotes Resistance to Chemoradiation Therapy In Vitro and Correlates with Treatment Failure in Patients with Esophageal Adenocarcinoma","volume":"22","author":"Bibby","year":"2016","journal-title":"Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/s41598-018-24232-2","article-title":"Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma","volume":"8","author":"Macgregor","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12967-018-1668-3","article-title":"Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma","volume":"16","author":"Borg","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Borg, D., Hedner, C., Nodin, B., Larsson, A., Johnsson, A., Eberhard, J., and Jirstr\u00f6m, K. (2016). Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. BMC Clin. Pathol., 16.","DOI":"10.1186\/s12907-016-0034-8"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamasurg.2014.3867","article-title":"Role of Repeat18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma","volume":"150","author":"Kukar","year":"2015","journal-title":"JAMA Surg."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lynam-Lennon, N., Maher, S.G., Maguire, A., Phelan, J., Muldoon, C., Reynolds, J.V., and O\u2019Sullivan, J. (2014). Altered Mitochondrial Function and Energy Metabolism Is Associated with a Radioresistant Phenotype in Oesophageal Adenocarcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100738"},{"key":"ref_60","first-page":"1201","article-title":"A perspective from countries using organized screening programs","volume":"101","author":"Miles","year":"2004","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s11605-016-3177-0","article-title":"Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma","volume":"20","author":"Alnaji","year":"2016","journal-title":"J. Gastrointest. Surg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/bjs.10627","article-title":"Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma","volume":"104","author":"Noble","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/SLA.0000000000000966","article-title":"Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer","volume":"260","author":"Shapiro","year":"2014","journal-title":"Ann. Surg."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3427\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:50:28Z","timestamp":1760140228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":63,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cancers14143427"],"URL":"https:\/\/doi.org\/10.3390\/cancers14143427","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}